| Primary |
| Atrial Fibrillation |
40.2% |
| Ventricular Tachycardia |
12.6% |
| Arrhythmia |
7.7% |
| Product Used For Unknown Indication |
7.6% |
| Drug Use For Unknown Indication |
5.0% |
| Hypertension |
4.1% |
| Atrial Flutter |
2.9% |
| Cardiac Failure |
2.7% |
| Supraventricular Tachycardia |
2.1% |
| Ventricular Fibrillation |
1.9% |
| Ventricular Arrhythmia |
1.9% |
| Prophylaxis |
1.6% |
| Type 2 Diabetes Mellitus |
1.4% |
| Tachyarrhythmia |
1.4% |
| Cardiac Disorder |
1.3% |
| Cardiac Failure Congestive |
1.3% |
| Insomnia |
1.2% |
| Gout |
1.1% |
| Tachycardia |
1.0% |
| Hyperlipidaemia |
1.0% |
|
| Pulmonary Fibrosis |
8.9% |
| Ventricular Tachycardia |
8.2% |
| Pulmonary Toxicity |
8.0% |
| Hyperthyroidism |
7.7% |
| Drug Interaction |
7.0% |
| Hypothyroidism |
6.7% |
| Weight Decreased |
6.0% |
| Torsade De Pointes |
5.4% |
| Toxicity To Various Agents |
5.4% |
| Tremor |
5.1% |
| Lung Disorder |
4.8% |
| Pneumonia |
3.6% |
| Rhabdomyolysis |
3.1% |
| Dyspnoea |
2.9% |
| Pneumonitis |
2.9% |
| Respiratory Failure |
2.9% |
| Ventricular Fibrillation |
2.9% |
| Vomiting |
2.9% |
| Interstitial Lung Disease |
2.8% |
| Drug Ineffective |
2.6% |
|
| Secondary |
| Atrial Fibrillation |
22.7% |
| Drug Use For Unknown Indication |
16.1% |
| Product Used For Unknown Indication |
14.5% |
| Ventricular Tachycardia |
11.8% |
| Hypertension |
6.4% |
| Cardiac Failure |
4.2% |
| Arrhythmia |
3.2% |
| Cardiac Disorder |
3.0% |
| Prophylaxis |
2.1% |
| Cardiac Failure Congestive |
2.1% |
| Thrombosis Prophylaxis |
1.9% |
| Supraventricular Tachycardia |
1.8% |
| Atrial Flutter |
1.7% |
| Insomnia |
1.5% |
| Ill-defined Disorder |
1.2% |
| Pain |
1.2% |
| Cardiac Failure Chronic |
1.2% |
| Aortic Valve Replacement |
1.1% |
| Pneumonia |
1.1% |
| Ventricular Fibrillation |
1.1% |
|
| Ventricular Tachycardia |
16.6% |
| Blood Bilirubin Increased |
12.5% |
| Torsade De Pointes |
6.5% |
| Syncope |
6.1% |
| Hepatic Steatosis |
5.4% |
| Drug Ineffective |
4.7% |
| Interstitial Lung Disease |
4.7% |
| Renal Failure Acute |
4.7% |
| Rhabdomyolysis |
4.7% |
| Atrial Fibrillation |
4.3% |
| Drug Interaction |
4.0% |
| Pneumonia |
3.2% |
| Vomiting |
3.2% |
| Weight Decreased |
3.2% |
| Renal Failure |
2.9% |
| International Normalised Ratio Increased |
2.7% |
| Paraesthesia |
2.7% |
| Ventricular Fibrillation |
2.7% |
| Hyperthyroidism |
2.5% |
| Hypotension |
2.5% |
|
| Concomitant |
| Product Used For Unknown Indication |
31.2% |
| Drug Use For Unknown Indication |
26.6% |
| Atrial Fibrillation |
8.6% |
| Hypertension |
6.9% |
| Cardiac Disorder |
2.8% |
| Coronary Artery Bypass |
2.5% |
| Nuclear Magnetic Resonance Imaging |
2.3% |
| Cardiac Failure |
2.1% |
| Prophylaxis |
2.0% |
| Multiple Myeloma |
1.8% |
| Pain |
1.7% |
| Osteoporosis |
1.6% |
| Arrhythmia |
1.6% |
| Diabetes Mellitus |
1.5% |
| Chronic Obstructive Pulmonary Disease |
1.3% |
| Blood Cholesterol Increased |
1.2% |
| Rheumatoid Arthritis |
1.2% |
| Cardiac Failure Congestive |
1.0% |
| Depression |
1.0% |
| Angiogram |
1.0% |
|
| Vomiting |
10.0% |
| Weight Decreased |
7.3% |
| Renal Failure Acute |
7.2% |
| Death |
6.9% |
| Pain |
6.4% |
| Ventricular Tachycardia |
6.1% |
| Renal Failure |
5.7% |
| Injury |
5.3% |
| Unevaluable Event |
4.9% |
| Pneumonia |
4.6% |
| Sepsis |
4.2% |
| Weight Increased |
4.2% |
| Atrial Fibrillation |
4.1% |
| Anxiety |
3.8% |
| Fear |
3.6% |
| International Normalised Ratio Increased |
3.2% |
| Syncope |
3.2% |
| Thrombocytopenia |
3.2% |
| Myocardial Infarction |
3.1% |
| Anhedonia |
3.0% |
|
| Interacting |
| Drug Use For Unknown Indication |
17.2% |
| Atrial Fibrillation |
15.0% |
| Product Used For Unknown Indication |
10.9% |
| Supraventricular Tachycardia |
7.0% |
| Ventricular Tachycardia |
5.9% |
| Overdose |
5.3% |
| Pneumonia |
4.9% |
| Myocardial Ischaemia |
4.7% |
| Arrhythmia |
4.0% |
| Ill-defined Disorder |
3.6% |
| Lower Respiratory Tract Infection |
3.0% |
| Atrial Flutter |
2.6% |
| Torsade De Pointes |
2.6% |
| Cardiac Failure |
2.2% |
| Immunosuppression |
2.2% |
| Sinus Arrhythmia |
2.1% |
| Antiplatelet Therapy |
1.7% |
| Hyperlipidaemia |
1.7% |
| Renal Failure Chronic |
1.7% |
| Anticoagulant Therapy |
1.5% |
|
| Drug Interaction |
26.1% |
| Supraventricular Tachycardia |
12.7% |
| Ventricular Fibrillation |
9.6% |
| Torsade De Pointes |
5.7% |
| Electrocardiogram Qt Prolonged |
5.1% |
| Cardiac Arrest |
4.5% |
| Renal Failure |
4.5% |
| Pneumonia |
3.2% |
| Rhabdomyolysis |
3.2% |
| Toxicity To Various Agents |
3.2% |
| Fall |
2.5% |
| Intentional Overdose |
2.5% |
| International Normalised Ratio Increased |
2.5% |
| Sinus Bradycardia |
2.5% |
| Thrombocytopenia |
2.5% |
| Cholelithiasis |
1.9% |
| Hepatic Enzyme Increased |
1.9% |
| Myopathy |
1.9% |
| Myositis |
1.9% |
| Neurotoxicity |
1.9% |
|
